Podcast explores emerging rapid‑acting and psychedelic therapies for treatment‑resistant depression

In a recent episode of BioSpace’s Denatured podcast, host Jennifer C. Smith‑Parker talks with Hans Eriksson, chief medical officer of FundaMental Pharma, and Steve Levine, chief patient officer at Compass Pathways.

The conversation centers on treatment‑resistant depression, a condition that remains difficult to manage despite existing therapies.

Both guests highlight new strategies that could change the field, including rapid‑acting antidepressants that aim for faster symptom relief and psychedelic‑based treatments that are being explored for their potential lasting benefits.

They suggest that these innovative approaches may eventually shift the current treatment paradigm and offer new hope for patients who have not responded to conventional options.